Cns Spectrums
-
Clinical Trial
Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD.
Guanfacine is a noradrenergic agonist that is believed to improve symptoms of attention-deficit/hyperactivity disorder (ADHD) through selective actions at alpha2A-adrenoceptors in the prefrontal cortex. A recent double-blind, multicenter trial supports the efficacy and safety of guanfacine extended release (GXR) for pediatric ADHD. This long-term, open-label extension was conducted to study the safety profile and effectiveness of GXR for up to 2 years. ⋯ Long-term treatment with GXR was generally safe for up to 24 months of treatment, and effectiveness was maintained over this treatment period.
-
Parkinson's disease is the second most common neurodegenerative disease following Alzheimer's disease. As there is no biomarker or diagnostic test available for the diagnosis of Parkinson's disease, diagnosis of this disorder can be challenging. ⋯ Non-motor symptoms may require special attention, such as the impulse control disorders that can be devastating to patients and their families. This Expert Review Supplement presents three cases that illustrate different aspects of Parkinson's disease, including diagnosis, non-motor symptoms, and treatment.